Pegylated Interferon Alpha-2b Monotherapy Versus Combination With Entecavir in HBeAg-negative Chronic Hepatitis B
Status:
Unknown status
Trial end date:
2013-12-01
Target enrollment:
Participant gender:
Summary
The outcome of treatment of chronic hepatitis B is determined by viral and host interaction,
thus the combination therapy of immunomodulator (PEG-IFN) and potent antiviral drug
(entecavir) should improve the response rate. In addition, the simultaneous assessment of
viral and host genetic factors associated with SVR may help to identify predictors of
treatment outcomes, which will in turn significant reduce the cost/effect of therapy